Patents by Inventor Ying Ji Buechler

Ying Ji Buechler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEGylated aspartyl-tRNA synthetase polypeptides
    Patent number: 9822353
    Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 21, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein
  • Aspartyl-tRNA synthetases
    Patent number: 9816084
    Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 14, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Kristi Helen Piehl, Jeffrey Greve, John D. Mendlein
  • PEGylated tyrosyl-tRNA synthetase polypeptides
    Patent number: 9714419
    Abstract: The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: July 25, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Jeffrey D. Watkins, Ying Ji Buechler, Chi-Fang Wu, Minh-Ha Do, Alain P. Vasserot, John D. Mendlein
  • Aspartyl-tRNA synthetase-Fc conjugates
    Patent number: 9688978
    Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: June 27, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Jeffrey D. Watkins, John D. Mendlein
  • PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES
    Publication number: 20150159148
    Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
    Type: Application
    Filed: December 6, 2012
    Publication date: June 11, 2015
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein
  • ASPARTYL-TRNA SYNTHETASE-FC CONJUGATES
    Publication number: 20140335087
    Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
    Type: Application
    Filed: December 27, 2012
    Publication date: November 13, 2014
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Jeffrey D. Watkins, John D. Mendlein
  • ASPARTYL-TRNA SYNTHETASES
    Publication number: 20140302075
    Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 9, 2014
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Kristi Helen Piehl, Jeffrey Greve, John D. Mendlein
  • PEGYLATED TYROSYL-TRNA SYNTHETASE POLYPEPTIDES
    Publication number: 20140255378
    Abstract: The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.
    Type: Application
    Filed: August 8, 2012
    Publication date: September 11, 2014
    Applicant: aTyr Pharma, Inc
    Inventors: Jeffrey D. Watkins, Ying Ji Buechler, Chi-Fang Wu, Minh-Ha Do, Alain P. Vasserot, John D. Mendlein